CDKN2A

(redirected from MTS1)
Also found in: Acronyms.

CDKN2A

A gene on chromosome 9p21 that encodes an alternate open reading frame (ARF) product, which acts as a tumour suppressor by binding to MDM2 and blocking its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits MDM2’s oncogenic activity, which would normally degrade p53, a tumour suppressor protein. CDKN2A also induces G2 arrest and apoptosis, independent of p53, by preventing the activation of cyclin B1/CDC2 complexes.

CDKN2A also binds to:
• BCL6, downregulating BCL6-induced transcriptional repression;
• E2F1 and MYC, blocking their transcriptional activator activity;
• HUWE1, repressing its ubiquitin ligase activity;
• TOP1/TOPOI, stimulating its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation.

CDKN2A interacts with:
• COMMD1 and promotes its “Lys63”-linked polyubiquitination;
• NPM1/B23, promoting its polyubiquitination and degradation and inhibiting rRNA processing;
• UBE2I/UBC9, enhacing sumoylation of some of its binding partners (e.g., MDM2 and E2F1).
References in periodicals archive ?
Experimental design and nomenclature for six independent groups assigned according to method type and complexity (N = 60) Behaviours 1 2 3 Group PIR1 PIR2 PIR3 Reading Reading & Reading & writing writing & clasping Observers 10 10 10 Group MTS1 MTS2 MTS3 Reading Reading & Reading & writing writing & clasping Observers 10 10 10
The researchers hope eventually to be able to influence this decision in tumor cells by adding back the MTS1 gene or administering a drug that mimics p16's braking activity.
Using this strategy, Myriad has made several major genetic discoveries during the past year, including the BRCA1 breast and ovarian cancer gene, the tumor suppressor function of the MTS1 gene in many types of cancer, and the localization of BRCA2, a hereditary breast cancer gene, to a small region of chromosome 13.